Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
893.5 USD | +1.17% | -0.64% | +1.83% |
04-26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
04-26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.83% | 95.28B | |
-2.17% | 103B | |
+2.82% | 22.15B | |
-15.88% | 21.02B | |
-8.56% | 18.15B | |
-41.01% | 16.73B | |
-14.25% | 16.05B | |
+4.28% | 13.68B | |
+32.52% | 12.17B | |
-23.75% | 8.24B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals : BMO Capital Adjusts Regeneron Pharmaceuticals' Price Target to $706 from $669, Keeps Outperform Rating